Clorox Appoints New CEO, CFO, COO

TL;DR

Clorox gets a new CEO, Brenda Freeman, starting Feb 5th. Jacobsen is interim CFO, Novak interim COO.

AI Summary

On January 23, 2025, The Clorox Company announced changes in its executive leadership. The company appointed Brenda L. Freeman as Chief Executive Officer and a member of the Board of Directors, effective February 5, 2025. Additionally, Kevin M. Jacobsen was appointed Interim Chief Financial Officer, and Laura L. Novak was appointed Interim Chief Operating Officer.

Why It Matters

This filing signals a significant leadership transition at Clorox, with a new CEO taking the helm, which could lead to strategic shifts and impact the company's future performance.

Risk Assessment

Risk Level: medium — Leadership changes, especially at the CEO level, can introduce uncertainty and signal strategic shifts, impacting investor confidence and operational execution.

Key Players & Entities

• The Clorox Company (company) — Registrant
• Brenda L. Freeman (person) — Appointed Chief Executive Officer and Board Member
• February 5, 2025 (date) — Effective date for Brenda L. Freeman's appointment
• Kevin M. Jacobsen (person) — Appointed Interim Chief Financial Officer
• Laura L. Novak (person) — Appointed Interim Chief Operating Officer
• January 23, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $1.00 — ge on which registered Common Stock - $1.00 par value CLX New York Stock Exchange
• $725,000 — increase in Mr. Bellet's base salary to $725,000 and an increase in his short-term incen
• $400,000 — ts that have an aggregate fair value of $400,000, which will vest over four years, and p
• $600,000 — with an aggregate target fair value of $600,000 and a three-year performance period end

Filing Documents

• clx4432551-8k.htm (8-K) — 25KB
• clx4432551-ex991.htm (EX-99.1) — 6KB
• clx4432551-8k1x1x1.jpg (GRAPHIC) — 30KB
• clx4432551-ex9911x1x1.jpg (GRAPHIC) — 26KB
• 0001206774-25-000035.txt ( ) — 311KB
• clx-20250123.xsd (EX-101.SCH) — 3KB
• clx-20250123_pre.xml (EX-101.PRE) — 24KB
• clx-20250123_lab.xml (EX-101.LAB) — 33KB
• clx4432551-8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On January 23, 2025, Kevin Jacobsen, Executive Vice President – Chief Financial Officer of The Clorox Company (the "Company"), provided notice of his intention to retire from the Company effective April 1, 2025, following nearly 30 years of service. Mr. Jacobsen will continue in an advisory capacity at the Company until June 2025. (c) On January 23, 2025, the Management Development and Compensation Committee (the "MDCC") of the Board of Directors of the Company appointed Luc Bellet, age 46, to be Executive Vice President – Chief Financial Officer, effective April 1, 2025. Mr. Bellet is currently the Company's Vice President – Treasurer, a position he has held since October 2023. Prior to this role, Mr. Bellet served as Vice President – Financial Planning & Analysis from April 2018 to October 2023. Mr. Bellet joined the Company in 2006 and has held a number of senior leadership roles in the Company's financial organization over the years, including in internal audit, Global Product Supply and various business units. In connection with Mr. Bellet's appointment, on January 23, 2025, the MDCC approved an increase in Mr. Bellet's base salary to $725,000 and an increase in his short-term incentive target from 50% to 100% of his salary, effective as of April 1, 2025. In addition, on April 1, 2025, Mr. Bellet will receive a grant of restricted stock units that have an aggregate fair value of $400,000, which will vest over four years, and performance shares with an aggregate target fair value of $600,000 and a three-year performance period ending June 30, 2027. Mr. Bellet has no familial relationships nor related party transactions with the Company that would require disclosure under Items 401(d) or 404(a) of Regulation S-K (17 CFR 229.401(d) and 229.404(a)) in connection with his appointment described above.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure A copy of the press release announcing the future Chief Financial Officer changes is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the Exhibit Index below. EXHIBIT INDEX Exhibit Description 99.1 Press Release dated January 28, 2025 of The Clorox Company 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CLOROX COMPANY Date: January 28, 2025 By: /s/ Angela Hilt Angela Hilt Executive Vice President – Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR